Strange Bedfellows: Amgen, J&J Work Together In Advance Of EPO Meeting
Executive Summary
Amgen is working with Johnson & Johnson to ensure that a consistent message regarding the safety profile of erythropoiesis-stimulating agents is presented to FDA's Oncologic Drugs Advisory Committee
You may also be interested in...
Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products
Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products
Biotechs Gain On Favorable M&A Landscape; Will Deal Prices Keep Rising?
The steady growth in the valuation of small and mid-size biotech firms over the last quarter may reflect the increasing leverage such companies have in merger and acquisition negotiations with big pharma